Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported Q1 EPS of ($1.39), $1.00 worse than the analyst estimate of ($0.39). Revenue for the quarter came in at $2.5 million versus the consensus estimate of $74.42 million.

For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) click here.